84 recruiting, 79 completed, 66 unknown, 42 not yet recruiting. 335 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 335 | Recruiting 84, Completed 79, Unknown 66, Not yet recruiting 42, Terminated 29, Active not recruiting 15, Withdrawn 15, Suspended 3, Enrolling by invitation 2 |
Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders Ginger, Placebo - Women With Coagulation Disorders | Early Phase 1 | Not yet recruiting | University of Valladolid | 74 | 2028-02-01 | 2026-05-19 |
| A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia GT737 Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 36 | 2027-05-01 | 2026-09-11 |
| A Clinical Study Evaluating the Safety and Preliminary Effectiveness of Induced Pluripotent Stem Cell-derived Platelets in Patients With Thrombocytopenia Caused by Allogeneic Hematopoietic Stem Cell Transplantation iPSC-derived platelets - Thrombocytopenia | Early Phase 1 | Not yet recruiting | Ruijin Hospital | 9 | 2026-12-30 | 2026-10-29 |
| Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies iMagic Injection (IMV101), iMagic Injection (IMV102) - Relapsed/Refractory Hematologic Malignancies | Early Phase 1 | Not yet recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-12-10 | 2026-11-04 |
| Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department Haloperidol - Cannabinoid Hyperemesis Syndrome | Early Phase 1 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-11-01 | 2026-09-01 |
| CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease | Early Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 5 | 2026-09-30 | 2026-05-15 |
| META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia Metabolically Armed Autologous CD19 CAR T-Cell therapy - Autoimmune Hemolytic Anemia (AIHA) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-09-20 | 2026-09-21 |
| Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia PID23 Injection - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Zhujiang Hospital | 18 | 2026-08-01 | 2026-07-10 |
| Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation MegaLT Injection - Thrombocytopenia, Hematologic Malignacies | Early Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 7 | 2026-07-31 | 2026-07-10 |
| Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) Iberdomide, CAR-T Leukapheresis, CAR-T Infusion - Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Not yet recruiting | Shambavi Richard | 22 | 2026-07-01 | 2026-07-27 |
| Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma RN9101 injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 19 | 2026-07-01 | 2026-06-10 |
| Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Chimeric Antigen Receptor T Cells (CAR-T) - Relapsed/Refractory Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Chulalongkorn University | 3 | 2026-06-01 | 2026-03-09 |
| CAR-T Cell Therapy for ALL CAR-T cell infusion - Relapsed Acute Lymphoblastic Leukemia (ALL) | Early Phase 1 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-10 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults. CTX001 With and Without Iron, CTX001 With Iron, CTX001 Multiple Dose - Anemia, Iron Deficiencies | Early Phase 1 | Recruiting | Cajal Therapeutics Inc. | 72 | 2026-06-01 | 2026-06-12 |
| A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. QI-019B Injection - Multiple Myeloma (MM) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-04-15 | 2026-04-20 |
| A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma IMV102 treatment - Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-04-14 | 2026-09-03 |
| Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) Arnovie101 Infusion Intravenous - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA) | Early Phase 1 | Recruiting | Circunited BioPharma (Shenzhen) Co., Ltd. | 5 | 2026-04-07 | 2026-06-05 |
| Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia Momelotinib, Azacitidine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 | 2026-03-19 | 2026-03-27 |
| Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL CD7 CAR-T cell intravenous infusion - T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-03-15 | 2026-03-17 |
| Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Early Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 2026-03-11 | 2026-11-12 |
Showing 20 of 335. Sign in to see all of them.
Multiple Myeloma (87) · Leukemia, Myeloid, Acute (54) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (36) · Hematologic Neoplasms (32) · Lymphoma, Non-Hodgkin (26) · Leukemia (22) · Recurrence (21) · Myelodysplastic Syndromes (19) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Anemia, Sickle Cell (15) · Lymphoma (12) · Lymphoma, B-Cell (11) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (9) · Primary Myelofibrosis (9) · Purpura, Thrombocytopenic, Idiopathic (9)
Hemic and Lymphatic Diseases (334) · Neoplasms (233) · Neoplasms by Histologic Type (210) · Immune System Diseases (193) · Immunoproliferative Disorders (163) · Lymphoproliferative Disorders (156) · Hemorrhagic Disorders (112) · Leukemia (107) · Cardiovascular Diseases (100) · Vascular Diseases (100) · Blood Protein Disorders (99) · Paraproteinemias (96) · Hemostatic Disorders (93) · Neoplasms, Plasma Cell (89)
Cyclophosphamide (20) · fludarabine (10) · Dexamethasone (9) · Lenalidomide (7) · Bortezomib (6) · Granulocyte Colony-Stimulating Factor (6) · Etoposide (5) · Filgrastim (5) · Melphalan (5) · Sirolimus (5) · Stem Cell Transplantation (5) · 68Ga-pentixafor (4) · Cytarabine (4) · Immunotherapy, Adoptive (4) · Mycophenolic Acid (4)
Zhejiang University (23) · Institute of Hematology & Blood Diseases Hospital, China (18) · M.D. Anderson Cancer Center (10) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (8) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (8) · Mayo Clinic (7) · Washington University School of Medicine (7) · Shanghai Changzheng Hospital (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Baylor College of Medicine (5) · iCell Gene Therapeutics (5) · Children's Hospital Medical Center, Cincinnati (4) · He Huang (4) · Hrain Biotechnology Co., Ltd. (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4)
China (152) · United States (127) · Australia (4) · Canada (3) · France (3) · Denmark (2) · Egypt (2) · Germany (2) · Sweden (2) · United Kingdom (2) · Bangladesh (1) · Czechia (1) · Greece (1) · Ireland (1) · Italy (1)
He Huang, MD (6) · Fang Liu, MD, PhD (5) · Hongyu Zhang, MD, PhD (5) · Elizabeth M Kang, M.D. (3) · Heng Mei, Ph.D&M.D (3) · Yongrong Lai, M.D. (3) · Farrokh Dehdashti, M.D. (2) · Jianmin Luo, PhD&MD (2) · John F DiPersio, M.D., Ph.D. (2) · John F Tisdale, M.D. (2) · Jonathan Powell, PhD (2) · Juan Du, Doctor (2) · Kailin Xu, M.D., Ph.D. (2) · Lei Zhang, MD (2) · Margaret Kasner, MD (2)
PMID 37192741, PMID 42705233, PMID 39501801, PMID 40540129, PMID 19793860, PMID 19819109, PMID 19965657, PMID 22094494, PMID 24034070, PMID 24899360, PMID 28245227, PMID 29272362, PMID 29426300, PMID 29616857, PMID 31405950, PMID 31776631, PMID 32298202, PMID 32611669, PMID 32826320, PMID 32840736, PMID 32989091, PMID 33439382, PMID 33626253, PMID 33779986, PMID 34651291, PMID 34677626, PMID 35177672, PMID 35349631, PMID 35468680, PMID 35576529, PMID 35973200, PMID 36189306, PMID 36719647, PMID 36725117, PMID 36762851, PMID 36808074, PMID 37077913, PMID 37093350, PMID 37272512, PMID 37658205, PMID 37735756, PMID 38143760, PMID 38181784, PMID 38230766, PMID 38592213, PMID 38703748, PMID 39172743, PMID 39238110, PMID 39265169, PMID 39827892
P30CA015083 (3), P30CA006973 (2), P30CA033572 (2), P30CA043703 (2), P30CA072720 (2), 2017 (1), 2019 (1), P01CA015396 (1), P01CA068484 (1), P01CA148600 (1), P30CA006516 (1), P30CA012197 (1), P30CA016672 (1), P30CA042014 (1), P30CA060553 (1)